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AH and 39 (23%) had masked AH. Two-hundred eighteen subjects (86%)
were treated with continuous positive airway pressure. Masked AH was not
associated with the severity of OSAS (AHI and the percentage of total sleep
time during which the oxygen saturation was <90% (SaO2<90%). However,
subjects with masked arterial hypertension have a worst metabolic risk profile
compared to normotensive patients.
Conclusions. Masked hypertension is frequent in OSAS patients and is not
associated with the severity of the OSAS.
Table – Results 
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Objective: To evaluate the prevalence rates of peripheral arterial disease
(PAD) diagnosed before and during the general practitioner (GP) consultation
following hospitalization for ischemic event.
Method: In a cross sectional study, 102 Belgian GPs recruited 505 patients
of 50 years, hospitalized within the last year for any ischemic event. The
Screening CardioVascular Lab (SCVL®, GenNov) automated combination of
the oscillometric determination of the ankle-brachial index (ABI) and of the
outcome of the Edinburgh questionnaire (EQ). This device integrated the case
report form.
Results: The patients were 69±11 years old; men were 63%. Their other
CV risk factors were: hypertension in 75%; dyslipidemia in 74%; sedentarily
in 53%; abdominal obesity in 52%; familial history of CVD in 38%; smoking
in 28%; diabetes in 22%. The arterial events, which induced the recent hospi-
talizations, were: acute in 71% of cases, planned for revascularization in 23%;
coronary in 50%, cerebral in 29%, aortic/peripheral in 15%. For at least their
hospitalization, 95% of patients were treated with antithrombotics, including
88% with antiplatelets. At the GP visit, PAD was unknown in 10% of cases
and previously diagnosed in 19%, including an appraisal exclusively on clin-
ical signs in 5% and a confirmation by Doppler ultrasonography or arteriog-
raphy in 13%. The EQ had a positive outcome in 16% of patients: the site of
claudication was typical in 85% of these; its severity, of grade 2 in 52%. The
patient ABI was of 0.95±0.20, <0.90 in 37% of patients and >1.30, in 3%. The
combination EQ~ABI was abnormal in 46%. 
Conclusion: In patients recently hospitalized for any ischemic event, the
“true” prevalence rate of PAD, as diagnosed prior to the GP visit, was 19%.
The “apparent” one, by using the SCVL® combining the ABI determination
and the Edinburgh questionnaire at the GP office, was 46%, despite the exten-
sive antithrombotic treatment. Even in a hospital setting, PAD is widely
underdiagnosed.
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Background: Obstructive sleep apnea syndrome (OSAS) is associated
with an increased risk of arterial hypertension (AH) and cardiovascular com-
plications. The aim of this study was to evaluate whether the AH profile,
already known or newly diagnosed, was associated with the severity of the
OSAS.
Methods: Clinical blood pressure and twenty-four-hour ambulatory blood
pressure monitoring were systematically recorded in 253 consecutive patients
with documented OSAS.
Results. In this cohort (mean age 51.3±9.5 years, 83% men, mean BMI
31.8±5.8 kg/m², mean Apnea-Hypopnea Index (AHI) 52.9±28.5%), 82 (32%)
had known AH, 91(36%) had newly diagnosed AH and 80 (32%) had no AH
including white coat effect (25 [15%]). Two hundred and nineteen patients
(86%) were treated with continuous positive airway pressure with no differ-
ence with regard to the AH profile (p=0.305 for trend). The AHI was higher
in OSAS hypertensive patients compared to patients without AH (Table) asso-
ciated with an increased rate of the metabolic syndrome and worst insulin
resistance profile.
Conclusions: We found a continuous relation between the severity of
OSAS, the presence of AH whether already known or newly diagnosed and
the metabolic profile in a large cohort of patients with treated OSAS.
Table – Results
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Objective: To evaluate the efficiency of adrenal imaging by an abdominal
CT scan as first line investigation in subjects with resistant hypertension when
Masked AH
n=39
No AH
n=80
p
Apnea-Hypopnea Index 48.9±23.8 47.7±24.4 0.810
SaO2 <90%,% 12.0±15.3 14.0±17.7 0.579
Age, years 49.6±6.8 49.6±9.4 0.995
Body mass index, kg/m² 30.1±5.5 30.0±5.4 0.947
Fasting glycemia, mg/dL 94±13 94±34 0.148
Homeostasis model assessment-
estimated insulin resistance 
(HOMA-IR)
3.9±2.9 2.5±2.8 0.031
Fasting triglyceridemia, mg/dL 170±110 130±90 0.004
CRP us, mg/L 4.9±6.6 3.8±2.5 0.980
Metabolic syndrome, n (%)
NCEP ATP III definition
13 (33) 10 (13) 0.007
Known 
AH
n=82
Newly 
diagnosed 
AH
n= 91
No AH
n=80
p
Apnea-Hypopnea Index 56.8±33.5 53.4±25.9 47.7±24.4 0.015
SaO2 <90%,% 19.0±22.0 18.0±20.0 14.0±17.7 0.158
Age, years 55.1±7.9 50.0±8.6 49.6±9.4 0.307
Body mass index, kg/m² 33.9±6.2 31.4±5.3 30.0±5.4 0.299
Fasting glycemia, mg/dL 106±29 97±16 94±34 <0.001
Homeostasis model 
assessment-estimated insulin 
resistance (HOMA-IR)
4.3±3.30 3.7±3.1 2.6 ±2.5 0.06
Fasting tryglyceridemia, 
mg/dL
170±150 158±94 130±90 <0.001
CRP us, mg/L 3.8±2.5 4.1±4.7 3.85±3.7 0.54
Metabolic syndrome, n (%)
NCEP ATP III definition
60 (73.2) 45 (50) 10 (12.5) <0.001
